FourThought Financial Partners LLC Lowers Stake in Sanofi (NASDAQ:SNY)

FourThought Financial Partners LLC reduced its position in shares of Sanofi (NASDAQ:SNY) by 6.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,130 shares of the company’s stock after selling 461 shares during the quarter. FourThought Financial Partners LLC’s holdings in Sanofi were worth $344,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Synergy Asset Management LLC purchased a new stake in shares of Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its stake in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares in the last quarter. Concord Wealth Partners boosted its stake in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares in the last quarter. Fortitude Family Office LLC boosted its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Up 2.1 %

NASDAQ:SNY opened at $54.89 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock’s fifty day moving average is $51.22 and its two-hundred day moving average is $52.56. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a market capitalization of $139.30 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SNY shares. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.